Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
← catalyst calendarNCT06307652 · readout in 296 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
4,800estimated
Sites
852
Countries
Argentina, Australia, Austria +36
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-12 | actual | When the study began enrolling |
| Primary completion | 2027-06-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure and Impaired Kidney Function
Interventions
- Drug: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Drug: balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Drug: dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
Primary outcome
what the primary-completion date above is the date OFTime to first occurrence of any of the components of the composite of: •CV death •HF hospitalisation •HF event without hospitalisation
measured Approximately 38 months
Publications
- PMID 39962632 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed